The FDA has approved agents that target IL-6 and downstream signaling pathways, such as IL-6, IL-6R, and JAKs, for the treatment of inflammatory diseases and myeloproliferative neoplasms 10. Here, IL6 is linked to myeloproliferative neoplasm.